Known targets — ChEMBL curated mechanism
DRD2DRD3DRD4GNRHRHRH1HTR2AHTR2CSLC6A2SLC6A4SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Pamoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.97 |
| ▸ | POLB | P06746 | 2/20 | 0.97 |
| ▸ | ME2 | P23368 | 1/20 | 0.74 |
| ▸ | ME1 | P48163 | 1/20 | 0.74 |
| ▸ | ME3 | Q16798 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.54 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | GALK1 | P51570 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL5012888 | 1.00 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL30293206 | 0.98 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL29362189 | 0.98 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL30293211 | 0.98 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL446833 | 0.98 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5721 | 0.98 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5014428 | 0.97 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL1055608 | 0.97 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5175194 | 0.97 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL9982931 | 0.97 | GPR35 (0.97) | GPR35POLBME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853750-A | Pamoic acid salt and crystal form of pennomelin, preparation method and application thereof | 南京迈诺威医药科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-109803654-B | Powder injection of donepezil hemipamoate, composition containing donepezil hemipamoate and preparation method of donepezil hemipamoate | 上海华汇拓医药科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-111454256-B | Pamoic acid lurasidone amorphous substance and preparation method and application thereof | 湖北中医药大学 | 2021-03-23 | — | — | CN | claimed |
| CN-111925294-A | Tolterodine pamoate and preparation method thereof | 济南大学 | 2020-11-13 | — | — | CN | claimed |
| EP-3703667-A1 | HYDROPHOBIC ION PAIRING AND FLASH NANOPRECIPITATION FOR FORMATION OF CONTROLLED-RELEASE NANOCARRIER FORMULATIONS | The Trustees of Princeton University (US) | 2020-09-09 | — | — | EP | claimed |
| US-20200268679-A1 | HYDROPHOBIC ION PAIRING AND FLASH NANOPRECIPITATION FOR FORMATION OF CONTROLLED-RELEASE NANOCARRIER FORMULATIONS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-08-27 | — | — | US | claimed |
| CN-111454256-A | Pamoic acid lurasidone amorphous substance and preparation method and application thereof | 湖北中医药大学 | 2020-07-28 | — | — | CN | claimed |
| WO-2008138783-A1 | EXPOSURE AGENT FOR DETECTION OF VITAMIN D | NORDIC BOISCIENCE A/S (DK) | 2008-11-20 | — | — | WO | claimed |
| US-12036264-B2 | Pharmaceutical compositions comprising teixobactin | NOVOBIOTIC PHARMACEUTICALS, LLC (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024148131-A1 | ORGANIC SOLVENT FREE DRUG MICROCRYSTALS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240189277-A1 | OPHTHALMIC FORMULATIONS FOR SUSTAINED NEUROPROTECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| EP-4378478-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-117915899-A | Percutaneous absorption preparation for treating dementia comprising memantine heptanoate | 东亚ST株式会社 | 2024-04-19 | — | — | CN | disclosed |
| CN-110678543-B | In vitro culture system and method of use thereof | 耶达研究及发展有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-1998032423-A1 | SUSTAINED-RELEASE MICROSPHERES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-07-30 | — | — | WO | disclosed |
| US-4291026-A | ISOLATION FROM MASH BY COMPLEXING WITH SALTS; ANIMAL FEEDS | AMERICAN CYANAMID COMPANY (US) | 1981-09-22 | — | — | US | disclosed |
| EP-0024508-A2 | Antibiotic BM123-gamma pamoate complexes, process for their preparation and compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1981-03-11 | — | — | EP | disclosed |
| US-4237120-A | ENHANCING GROWTH RATE OF MEAT ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1980-12-02 | — | — | US | disclosed |
| US-4044133-A | FEED SUPPLEMENT, POULTRY, THIENO-PYRIDINE, OR FURO-PYRIDINE BASE N | MERCK & CO., INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-4006143-A | COCCIDIOSTATS | MERCK & CO., INC. (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036264-B2 | Pharmaceutical compositions comprising teixobactin | PHOSPHO1, PLIN5, FNTA | GPR35 2597/4885POLB 2725/4885ME2 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.